| 标题 |
Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer |
| 网址 | |
| DOI | |
| 其它 |
期刊:The Lancet Regional Health - Western Pacific 作者:Yuankai Shi; Gongyan Chen; Xiang Wang; Yunpeng Liu; Lin Wu; et al 出版日期:2024-07-01 |
| 求助人 | |
| 下载 | 求助已完成,仅限求助人下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)